导师风采
王佳玉
个人信息
Personal Information
- 性别：女
- 导师类型：硕士生导师
- 职称：主任医师
- 该职称任职时间：2018
联系方式
Contact Information
- 所属院系：肿瘤医院
- 所属专业：肿瘤学
- 邮箱 : drwangjy@126.com
- 工作电话 : 87788120
个人简介
Personal Profile
中国医学科学院肿瘤医院内科 主任医师，硕士生导师，主要从事肿瘤内科治疗和抗肿瘤药物临床研究。专业方向为乳腺癌、软组织肉瘤。现任中国中医药研究促进会乳腺病分会 常委、北京乳腺病防治学会健康管理专业委员会 常委、北京乳腺病防治学会肿瘤免疫治疗专业委员会 常委、中国女医师协会乳腺疾病研究中心常委、中国抗癌协会临床肿瘤学协作专业委员会肉瘤专家委员会 常委、北京医学会奖励基金会脑转移分会副主任委员、中国抗癌协会乳腺癌专业委员会青年委员会委员等职，以及《临床药物治疗杂志》特约审稿人、《中华乳腺病杂志（电子版）》中青年编委、《中国医学论坛报.肿瘤周刊》特约编委。在国内外杂志发表论文百余篇，参与编写《实用肿瘤内科》等著作十余部，承担多项临床科研课题和国际国内抗癌新药临床试验。
团队简介
Team Profile
待补充更新
- 研究方向Research Directions
肿瘤内科治疗,乳腺癌专业,软组织肉瘤
- 在校研究生Current Graduate Students
硕士研究生 2 名，博士研究生 0 名
- 科研项目Research Projects
| # | 项目名称 | 起止日期 | 金额 | 项目类型 | 本人角色 |
|---|---|---|---|---|---|
| 1 | 我国实体瘤新一代生物疗法发展战略研究 | 2024-05 —— 2025-04 | 23万元 | 参与在研的国家或省部级科研项目 | 参与者 |
| 2 | 我国肿瘤精准诊疗现状、挑战及应对策略研究 | 2023-10 —— 2026-09 | 75万元 | 参与在研的国家或省部级科研项目 | 参与者 |
- 发表论文Papers
| # | 论文题目 | 期刊名称 | 发表年份 | 论文署名 |
|---|---|---|---|---|
| 1 | Trastuzumab treatment after progression in HER2-positive metastatic breast cancer following relapse of trastuzumab-based regimens: a meta-analysis | Cancer Management and Research | 2019-05 | 通讯作者 |
| 2 | Germline mutation landscape of Chinese patients with familial breast/ovarian cancer in a panel of 22 susceptibility genes | Cancer Medicine | 2019-05 | 第一作者 |
| 3 | Clinicopathological characteristics and prognosis of breast cancer with special histological types: A surveillance, epidemiology, and end results database analysis | Breast | 2020-12 | 通讯作者 |
| 4 | Comparative efficacy and safety of CDK4/6 and PI3K/AKT/mTOR inhibitors in women with hormone receptor-positive, HER2-negative metastatic breast cancer: a systematic review and network meta-analysis | Current Problems in Cancer | 2020-12 | 通讯作者 |
| 5 | Prognostic Model and Nomogram for Estimating Survival of Small Breast Cancer: A SEER-based Analysis | Clinical Breast Cancer | 2021-10 | 通讯作者 |
| 6 | Cutaneous adverse events associated with immune checkpoint blockade: A systematic review and meta-analysis | Critical Reviews in Oncology/Hematology | 2021-07 | 第一作者 |
| 7 | Sex-Based Heterogeneity in the Clinicopathological Characteristics and Prognosis of Breast Cancer: A Population-Based Analysis | Frontiers in Oncology | 2021-02 | 通讯作者 |
| 8 | Clinicopathological Characteristics and Prognosis of Squamous Cell Carcinoma of the Breast: A Population-Based Analysis | Cancer Control | 2021-10 | 通讯作者 |
| 9 | Profile, treatment patterns, and influencing factors of anthracycline use in breast cancer patients in China: A nation-wide multicenter study | Cancer Medicine | 2021-10 | 通讯作者 |
| 10 | Novel biomarkers and prediction model for the pathological complete response to neoadjuvant treatment of triple-negative breast cancer | Journal of Cancer | 2021-01 | 通讯作者 |
| 11 | Endocrine Therapy for Hormone Receptor-Positive Advanced Breast Cancer: A Nation-Wide Multicenter Epidemiological Study in China | Frontiers in Oncology | 2021-02 | 通讯作者 |
| 12 | Randomized and dose-escalation trials of recombinant human serum albumin /granulocyte colony-stimulating factor in patients with breast cancer receiving anthracycline-containing chemotherapy | BMC Cancer | 2021-03 | 通讯作者 |
| 13 | Comparative Efficacy of Tyrosine Kinase Inhibitors and Antibody-Drug Conjugates in HER2-Positive Metastatic Breast Cancer Patients with Brain Metastases: A Systematic Review and Network Meta-Analysis | Cancers | 2022-07 | 通讯作者 |
| 14 | Clinicopathological Characteristics and Prognosis of HER2-Low Early-Stage Breast Cancer: A Single-Institution Experience | Frontiers in Oncology | 2022-06 | 通讯作者 |
| 15 | Clinicopathological characteristics and prognosis of microinvasive breast cancer: A population-based analysis | Cancer Medicine | 2022-12 | 通讯作者 |
| 16 | The impact of hormone receptor on the clinical outcomes of HER2-positive breast cancer: a population-based study | International Journal of Clinical Oncology | 2022-04 | 通讯作者 |
| 17 | Optimal Choice as First-Line Therapy for Patients with Triple-Negative Breast Cancer: A Bayesian Network Meta-Analysis | Current Oncology | 2022-11 | 通讯作者 |
| 18 | Efficacy and Safety of Bevacizumab in Pretreated Metastatic Breast Cancer: A Systematic Review and Meta-Analysis | Oncology Research and Treatment | 2022-09 | 通讯作者 |
| 19 | Predictive value of topoisomerase II alpha protein for clinicopathological characteristics and prognosis in early breast cancer | Breast Cancer Research and Treatment | 2022-06 | 通讯作者 |
| 20 | CDK4/6 inhibitors versus PI3K/AKT/mTOR inhibitors in women with hormone receptor-positive, HER2-negative metastatic breast cancer: An updated systematic review and network meta-analysis of 28 randomized controlled trials | Frontiers in Oncology | 2022-08 | 通讯作者 |
| 21 | A phase Ib study of TQB2450 plus anlotinib in patients with advanced triple-negative breast cancer | iScience | 2023-05 | 第一作者 |
| 22 | Clinical efficacy of fulvestrant versus exemestane as first-line therapies for Chinese postmenopausal oestrogen-receptor positive /human epidermal growth factor receptor 2 -advanced breast cancer (FRIEND study) | European Journal of Cancer | 2023-05 | 第一作者 |
| 23 | New insights into HER2-low breast cancer brain metastasis: A retrospective analysis | Breast | 2024-02 | 通讯作者 |
| 24 | Predictive biomarkers of response and survival following immunotherapy with a PD-L1 inhibitor benmelstobart (TQB2450) and antiangiogenic therapy with a VEGFR inhibitor anlotinib for pretreated advanced triple negative breast cancer | Signal Transduction and Targeted Therapy | 2023-11 | 通讯作者 |
| 25 | Impact of HER2-low expression on the efficacy of endocrine therapy with or without CDK4/6 inhibitor in HR-positive/HER2-negative metastatic breast cancer: A prospective study | Thoracic Cancer | 2024-04 | 通讯作者 |
| 26 | Identifying the optimal therapeutics for patients with hormone receptor-positive, HER2-positive advanced breast cancer: a systematic review and network meta-analysis | ESMO Open | 2023-06 | 通讯作者 |
- 科研获奖Research Awards
无
- 研究成果Research Findings
| # | 成果类型 | 项目/专利/新品种名称 |
|---|---|---|
| 1 | 出版高水平专著 | 应对乳腺癌专家谈 |